[The P-phenomenon].
D000818:Animals; D001285:Atropine / Q000008:administration & dosage; D003093:Colitis, Ulcerative / Q000097:blood*; D003106:Colon; D004106:Dilatation / Q000187:drug effects; D004983:Ethanolamines / Q000008:administration & dosage; D006801:Humans; D008198:Lymph Nodes / Q000032:analysis; D008643:Mesentery / Q000098:blood supply*; D008833:Microcirculation / Q000187:drug effects*; D051381:Rats; D012039:Regional Blood Flow / Q000187:drug effects; D014020:Tissue Extracts / Q000494:pharmacology; D014043:Tolazoline / Q000008:administration & dosage; D014662:Vasoconstrictor Agents / Q000032:analysis / Q000097:blood*; D014665:Vasodilator Agents / Q000008:administration & dosage; D014666:Vasomotor System / Q000187:drug effects; D005719:gamma-Globulins / Q000032:analysis
D004983:Ethanolamines; D014020:Tissue Extracts; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D005719:gamma-Globulins; D001285:Atropine; D014043:Tolazoline
Das P-Phänomen.